ArticleBreast cancer (Tokyo, Japan)2026
Prognostic model for pulmonary metastasis in patients with HER2-positive breast cancer: a population-based study.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methodological considerations in prognostic modeling for HER2-positive breast cancer with lung metastasis.Breast cancer (Tokyo, Japan) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung metastasis is an important adverse prognostic factor in patients with HER2-positive breast cancer. However, a lack of an accurate estimation of the prognosis of patients with lung metastasis and the validation of population-based models has been observed. In this study, we aimed to establish a nomogram based on the surveillance, epidemiology, and end results (SEER) database to determine the prognostic factors associated with lung metastasis and evaluate the individualized survival of patients with lung metastasis.
methodsThis study included 613 patients diagnosed with HER2-positive breast cancer with lung metastasis (HER2 + BC-LM) from the SEER database and randomly divided them into two groups: (1) training group (n = 432) and (2) test group (n = 181). Based on the univariate and multivariate Cox regression analyses, we assessed the impact of multiple variables on the survival of the patients in the training group and constructed a nomogram to predict the survival probabilities of the patients at 6 months, 1 year, and 2 years. Furthermore, the nomogram was validated by the concordance index (C-index) and calibration plots.
resultsA prognostic model for predicting the prognosis of patients with HER2 + BC-LM was established and validated. For the patients diagnosed with HER2 + BC-LM, the C-index (0.813 in the training group and 0.787 in the validation group, respectively) and calibration plots revealed that the prognostic accuracy and clinical applicability of the nomogram were acceptable. The surgical resection of the primary tumor and chemotherapy were found to be significantly associated with better overall survival (OS).
conclusionA sensitive and discriminatory model was established to predict the OS of patients with HER2 + BC-LM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.